Paul, thanks for the research and sharing the arti

Paul, thanks for the research and sharing the articles. They provide context from the other side of the deals and the other side of the world. Since the beginning of COVID I have been begging for a vaccine platform that can mutate (and provide longer immunity) along with these constantly changing viruses. I'm not sure if Ii-key is it, but it seems to fit better than the more popular vaccines in the public consciousness.

Any of us that have been here since bird flu have seen the periodic evolution of SARS type viruses. The viruses come and go and funding and interest wane accordingly. This virus is not going anywhere, except into more and more victims. The symptoms vary so much from person to person that its vaccine has to be more complex than one size fits all. Once again, I think it bears repeating that Dr. EvH has been working on a vaccine platform for 20 years. Time and money (it appears) are on our side this time. Peptides are being ruled in and out, even as we wait for the investing world to discover GNBT/NGIO. COVID is not only something we die with, but given the proper platform, it may be the something we can live with.

I am not a medical researcher, nor do I have a scientific background. I am merely a long time GNBT shareholder. These past 14, nearly 15, years have taught me a lot, but my scenario above may be scientifically inaccurate in some points. For that I apologize, but I think you guys know what I mean.